Chronic Hepatitis News

VIENNA — In this exclusive video from the International Liver Congress 2019, Bajaj S. Jasmohan, MD, from the Virginia Commonwealth University and the McGuire VA Medical Center, discusses results from a study in which plasma metabolomics showed systemic differences in circulating lipid metabolites in people who followed a Middle Eastern diet vs. a standard Western Diet.

VIENNA — A combination of a core protein inhibitor and nucleos(t)ide analogue therapy brought hepatitis B virus RNA and DNA below levels of quantification, pointing toward the possibility of a cure, according to a presenter at the International Liver Congress.

VIENNA — A combination of Myrcludex with interferon produced undetectable levels of hepatitis D and significant lowering of hepatitis B virus, according to data presented during the International Liver Congress 2019.

VIENNA — Use of adenovirus derived from chimpanzees showed increased activity and sustainability of T cell activation in an early study of a vaccine for hepatitis C virus, according to new data presented during the International Liver Congress.

VIENNA — Epidemiological modelling showed that scale-up of hepatitis B mother-to-child transmission intervention and treatment in Africa will be as important in the progress to elimination as infant vaccination, according to a presentation at the International Liver Congress 2019.

VIENNA — A real-world analysis of Mavyret for hepatitis C showed patients with key comorbidities such as psychiatric disorders and substance abuse achieved high rates of sustained virologic response with improvements in patient-reported outcomes, according to a presentation at the International Liver Congress 2019.

For the treatment of chronic hepatitis C genotype 1 through 6 infections, glecaprevir and pibrentasvir demonstrated safety and efficacy in patients with compensated liver disease, including those with chronic kidney disease stage 4 or 5, according to results pooled from nine phase 2 and 3 trials.

Hearts from donors with hepatitis C virus are safe for transplantation, and the recipients respond to HCV treatment after transplantation, according to data presented at the Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.

Results from a recent study showed that a multifaceted intervention including provider and patient education, electronic medical record-enabled best practice alert, and increased hepatitis C treatment capacity significantly increased hepatitis C screening.

The Louisiana Department of Health selected Asegua Therapeutics, a subsidiary of Gilead Sciences, as their pharmaceutical partner in a “subscription style” payment plan designed to provide state residents with access to hepatitis C treatment, according to a press release from the department.